Related Experiment Video

Updated: Oct 9, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 22, 2014

10.0K

Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited

Sonja Loges1, Massimiliano Mazzone, Philipp Hohensinner

  • 1Vesalius Research Center, VIB, B-3000 Leuven, Belgium.

Cancer Cell
|March 3, 2009
PubMed

Insights

Vascular Endothelial Growth Factor (VEGF) inhibitors slow primary tumor growth but may increase cancer invasiveness and metastasis. This explains drug resistance and prompts new treatment strategies for antiangiogenic medicine.

Area of Science:

  • Oncology
  • Cancer Biology
  • Translational Medicine

Background:

  • Angiogenesis inhibitors are used in cancer therapy but often show limited survival benefits due to tumor resistance.
  • Tumor cells develop evasive resistance mechanisms against antiangiogenic therapies.

Discussion:

  • VEGF inhibitors reduce primary tumor growth but paradoxically enhance tumor invasiveness and metastasis.
  • These divergent effects contribute to understanding resistance to antiangiogenic drugs.

Key Insights:

  • VEGF inhibitors can promote tumor spread, complicating cancer treatment.
  • Understanding the dual role of VEGF inhibitors is crucial for effective cancer therapy.

Outlook:

  • Future research should focus on optimizing antiangiogenic therapy to overcome resistance and prevent metastasis.
  • Developing novel therapeutic strategies that combine VEGF inhibition with other treatments is essential.

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 29, 2019

7.9K
Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay09:03

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay

Published on: June 29, 2023

1.5K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...